Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Anatara Lifesciences Ltd ( (AU:ANR) ) has provided an announcement.
Anatara Lifesciences Ltd has completed the final allocation of shares under Tranche 2 of its two-tranche placement, issuing 66,352,417 ordinary shares. Additionally, 4,000,000 unlisted options were allotted to the Lead Manager, exercisable at $0.025 each and expiring in three years. This strategic move is expected to bolster Anatara’s financial position, supporting its ongoing product development and market expansion efforts.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd (ASX:ANR) is engaged in developing and commercializing innovative, evidence-based health products, particularly focusing on gastrointestinal tract conditions. The company aims to address significant unmet needs in human health and is committed to delivering tangible outcomes for patients while providing strong value for shareholders.
Average Trading Volume: 3,398,674
Technical Sentiment Signal: Sell
Current Market Cap: A$2.97M
See more insights into ANR stock on TipRanks’ Stock Analysis page.